Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

Ipsen announces changes to its Executive Committee

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma